Michael Mack speaks to Allan Schwartz, a principal investigator of the EARLY TAVR trial, who explains how it informs patient management.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.